The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Insights into the TARMAC study: time-limited ibrutinib and tisa-cel in patients with R/R MCL
Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, shares some insights into the Phase II TARMAC study (NCT04234061), which is evaluating the safety and efficacy of time-limited ibrutinib in combination with tisagenlecleucel (tisa-cel) in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). Dr Minson first comments on the rationale behind combining Bruton’s tyrosine kinase (BTK) inhibitors and CAR-T cell therapy, and the need to improve treatment options for patients with R/R MCL. Following this, Dr Minson highlights the overall response rate (ORR) observed, and comments on the potential role of this treatment combination in patients with R/R disease. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche: Honoraria, Research Funding; Novartis: Other: Travel support, Research Funding.
